July 30, 2025
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
July 30, 2025
First-half 2025 results
Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in…
July 30, 2025
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis(3)…
July 30, 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2025
Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025 Name of…
July 30, 2025
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) — Bio Usawa Biotechnology, Ltd. (Bio Usawa),…
July 29, 2025
BMS, Bain Capital create new company to focus on therapies for autoimmune diseases
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will…
July 29, 2025
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…
July 29, 2025
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from…
July 29, 2025
Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results
Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4…
July 29, 2025
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…